Cambium Bio (ASX:CMB) has entered into a term sheet with Keke Medtech, granting exclusive worldwide rights to develop and commercialize the company's proprietary human platelet lysate-derived fibrin biologic product for dental and oral wound healing applications, according to a Tuesday Australian bourse filing.
The deal includes an upfront payment of $250,000, of which $25,000 has already been received.
The deal also includes development milestones of up to $1.75 million and 10% royalties on the first $10 million and 13% thereafter.
The company will also receive a 20% share of non-royalty sublicense revenues.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments